GSA CAPITAL PARTNERS LLP

Position in EDIT — Editas Medicine, Inc.

CIK 1362033 LONDON, X0

Position in EDIT

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$1,073,000

-$93,058 QoQ

Shares Held

434,413

-23.6% QoQ

Ownership

0.444%

of shares outstanding

% of Portfolio

0.08%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2021

14 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $101,563,069 across 163 Biotechnology names. EDIT ranks #35 (1.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	3,831	$2,959,983
2	ARDX	Ardelyx, Inc.	473,061	$2,833,635
3	NTLA	Intellia Therapeutics, Inc.	178,301	$2,285,818
4	NUVB	Nuvation Bio Inc.	495,792	$2,126,947
5	RXRX	Recursion Pharmaceuticals, Inc.	669,568	$2,055,573
6	WVE	Wave Life Sciences Ltd.	282,719	$2,049,712
7	SRPT	Sarepta Therapeutics, Inc.	90,960	$1,979,289
8	IOVA	Iovance Biotherapeutics, Inc.	557,085	$1,955,368

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,073,000	434,413	-23.6%	Shares	Sole	2026-05-08
2025-12-31	$1,166,058	568,809	+590.8%	Shares	Sole	2026-02-06
2025-06-30	$181,154	82,343	-54.9%	Shares	Sole	2025-07-22
2024-09-30	$623,092	182,725	+89.0%	Shares	Sole	2024-11-05
2024-06-30	$451,612	96,705	+104.0%	Shares	Sole	2024-08-15
2024-03-31	$351,722	47,402	+135.4%	Shares	Sole	2024-05-03
2023-09-30	$157,099	20,141	-2.0%	Shares	Sole	2023-11-15
2023-03-31	$148,980	20,549	+9.6%	Shares	Sole	2023-05-12
2022-12-31	$166,277	18,746	-8.6%	Shares	Sole	2023-02-13
2022-09-30	$250,993	20,506	-70.3%	Shares	Sole	2022-11-14
2022-06-30	$816,270	69,000	+469.1%	Shares	Sole	2022-08-09
2022-03-31	$230,598	12,124	+8.2%	Shares	Sole	2022-05-11
2021-12-31	$297,386	11,201	+63.2%	Shares	Sole	2022-02-14
2021-09-30	$281,973	6,864	—	Shares	Sole	2021-11-12
No filing history on record for this holder in this stock.